Peptide Critic Community

@Stevepep said:

@Newenough how did you get in touch with them

Website has a WhatsApp link.

@SoySebastian said:

IDK BUT JEEP BEING TIER B IS KINDA WILD, too much distrust in the community.

The criteria only included testing related items at this point. I'd like to expand into customer oriented and satisfaction as well. Just having products testing is only part of it a good business. Please provide and details of you can. I'll through in a few and see what we get.

@stevepep
I would disagree that it's "lying", but more my prompting criteria was not aligned with the reality of the situation. One would expect refinement and adjust as need. If there are any suggestions from the community on adding more details or refining please let me know!

Grok's reply:
Thanks for the detailed reply — this is exactly the kind of practical insight the community needs.
The points about Nexaph labeling practices make a lot of sense. Many report that Nexaph primarily labels the outer box rather than individual vials, which explains the frequent "no label" or handwritten appearances in public tests. The Finnrick submission process (dropdown selection, free test bias toward popular vendors, and penalties for missing batch IDs) can lead to misattribution and unfair downgrades when testers select a listed vendor instead of the actual source.
This highlights a real traceability challenge for gray-market peptides. Even with strong purity and identity numbers showing up on many Janoshik reports for Nexaph, the gaps in vial-level batch marking make it harder to confidently link public test results to specific purchased vials (especially when relying on cap/vial colors or timing).
Bottom line for buyers and testers: Nexaph remains a selective / higher-caution option (Tier C) under a purity/identity/endotoxin-focused lens. It shows good potential on paper but carries extra verification risk compared to vendors with clearer vial labeling and more consistent blind test matching. Prioritizing independent tests, cap/vial color correlation, and shared group testing continues to be the most reliable approach across all vendors in this space.
Appreciate the correction — this kind of feedback helps everyone refine their sourcing and testing strategies. Out of curiosity, I will refine the criteria to limit downgrading due to potential vial labeling issues and see where it lands. As I am a frequent Nexpah customer, I am biased...lol.

Nexpah (Nexaph) Reevaluation (Janoshik-heavy focus, overfill and vial labeling/traceability issues fully discounted)

Tier B (Solid - Good with Verification)
Strengths: Strong and consistent high purity (typically 99.8–99.9%+ median) and excellent identity pass rates (~99–100%) across dozens of recent Janoshik/Finnrick tests for both tirzepatide and retatrutide. Multiple examples show clean or low endotoxin results (below LOQ or low).
Limitations: Notable batch-to-batch variability in overall scores remains, even on core quality metrics.
Summary: Discounting labeling concerns, Nexaph performs at a solid Tier B level based on available purity, identity, and endotoxin data. It is a viable option with verification (e.g., group testing on new batches) but still benefits from cross-checking recent public tests due to variability.